Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.

Oliver Illini; Hannah Fabikan; Aurélie Swalduz; Anders Vikström; Dagmar Krenbek; Michael Schumacher; Elizabeth Dudnik; Michael Studnicka; Ronny Öhman; Robert Wurm; Luciano Wannesson; Nir Peled; Waleed Kian; Jair Bar; Sameh Daher; Alfredo Addeo; Ofer Rotem; Georg Pall; Alona Zer; Akram Saad; Tanja Cufer; Hadas Gantz Sorotsky; Sayed M S Hashemi; Katja Mohorcic; Ronen Stoff; Yulia Rovitsky; Shoshana Keren-Rosenberg; Thomas Winder; Christoph Weinlinger; Arschang Valipour; Maximilian J Hochmair

doi:10.1177/17588359221103206

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.

Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka (Co-author), Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram SaadTanja Cufer, Hadas Gantz Sorotsky, Sayed M S Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J Hochmair

Department of Pneumology

Research output: Contribution to journal › Original Article › peer-review

20 Citations (Web of Science)

Original language	English
Pages (from-to)	17588359221103206
Journal	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume	14
DOIs	https://doi.org/10.1177/17588359221103206
Publication status	Published - 2022

Keywords

14 MUTATIONS
ACQUIRED-RESISTANCE
INHIBITORS
AMPLIFICATION
NSCLC

Access to Document

10.1177/17588359221103206

Cite this

Illini, O., Fabikan, H., Swalduz, A., Vikström, A., Krenbek, D., Schumacher, M., Dudnik, E., Studnicka, M., Öhman, R., Wurm, R., Wannesson, L., Peled, N., Kian, W., Bar, J., Daher, S., Addeo, A., Rotem, O., Pall, G., Zer, A., ... Hochmair, M. J. (2022). Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 14, 17588359221103206. https://doi.org/10.1177/17588359221103206

@article{15da069232f6469b942ca231fe140a77,

title = "Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.",

keywords = "14 MUTATIONS, ACQUIRED-RESISTANCE, INHIBITORS, AMPLIFICATION, NSCLC",

author = "Oliver Illini and Hannah Fabikan and Aur{\'e}lie Swalduz and Anders Vikstr{\"o}m and Dagmar Krenbek and Michael Schumacher and Elizabeth Dudnik and Michael Studnicka and Ronny {\"O}hman and Robert Wurm and Luciano Wannesson and Nir Peled and Waleed Kian and Jair Bar and Sameh Daher and Alfredo Addeo and Ofer Rotem and Georg Pall and Alona Zer and Akram Saad and Tanja Cufer and Sorotsky, \{Hadas Gantz\} and Hashemi, \{Sayed M S\} and Katja Mohorcic and Ronen Stoff and Yulia Rovitsky and Shoshana Keren-Rosenberg and Thomas Winder and Christoph Weinlinger and Arschang Valipour and Hochmair, \{Maximilian J\}",

note = "Studnicka: Department of Pneumology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria",

year = "2022",

doi = "10.1177/17588359221103206",

language = "English",

volume = "14",

pages = "17588359221103206",

journal = "THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY",

issn = "1758-8340",

}

Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, HG, Hashemi, SMS, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, MJ 2022, 'Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.', THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol. 14, pp. 17588359221103206. https://doi.org/10.1177/17588359221103206

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. / Illini, Oliver; Fabikan, Hannah; Swalduz, Aurélie et al.
In: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol. 14, 2022, p. 17588359221103206.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.

AU - Illini, Oliver

AU - Fabikan, Hannah

AU - Swalduz, Aurélie

AU - Vikström, Anders

AU - Krenbek, Dagmar

AU - Schumacher, Michael

AU - Dudnik, Elizabeth

AU - Studnicka, Michael

AU - Öhman, Ronny

AU - Wurm, Robert

AU - Wannesson, Luciano

AU - Peled, Nir

AU - Kian, Waleed

AU - Bar, Jair

AU - Daher, Sameh

AU - Addeo, Alfredo

AU - Rotem, Ofer

AU - Pall, Georg

AU - Zer, Alona

AU - Saad, Akram

AU - Cufer, Tanja

AU - Sorotsky, Hadas Gantz

AU - Hashemi, Sayed M S

AU - Mohorcic, Katja

AU - Stoff, Ronen

AU - Rovitsky, Yulia

AU - Keren-Rosenberg, Shoshana

AU - Winder, Thomas

AU - Weinlinger, Christoph

AU - Valipour, Arschang

AU - Hochmair, Maximilian J

N1 - Studnicka: Department of Pneumology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria

PY - 2022

Y1 - 2022

KW - 14 MUTATIONS

KW - ACQUIRED-RESISTANCE

KW - INHIBITORS

KW - AMPLIFICATION

KW - NSCLC

U2 - 10.1177/17588359221103206

DO - 10.1177/17588359221103206

M3 - Original Article

C2 - 35720834

SN - 1758-8340

VL - 14

SP - 17588359221103206

JO - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

JF - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

ER -